A detailed history of Black Rock Inc. transactions in Aura Biosciences, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 3,005,362 shares of AURA stock, worth $33.1 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,005,362
Previous 2,444,841 22.93%
Holding current value
$33.1 Million
Previous $19.2 Million 18.38%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$6.81 - $7.89 $3.82 Million - $4.42 Million
560,521 Added 22.93%
3,005,362 $22.7 Million
Q1 2024

May 10, 2024

BUY
$7.09 - $9.24 $2.45 Million - $3.2 Million
346,096 Added 16.49%
2,444,841 $19.2 Million
Q4 2023

Feb 13, 2024

BUY
$7.02 - $11.98 $1.65 Million - $2.81 Million
234,719 Added 12.59%
2,098,745 $18.6 Million
Q3 2023

Nov 13, 2023

SELL
$8.97 - $12.38 $72,710 - $100,352
-8,106 Reduced 0.43%
1,864,026 $16.7 Million
Q2 2023

Aug 11, 2023

BUY
$8.51 - $13.33 $4.6 Million - $7.21 Million
541,032 Added 40.65%
1,872,132 $23.1 Million
Q1 2023

May 12, 2023

BUY
$8.88 - $12.11 $2.47 Million - $3.37 Million
277,973 Added 26.4%
1,331,100 $12.4 Million
Q4 2022

Feb 13, 2023

BUY
$9.86 - $14.59 $391,165 - $578,814
39,672 Added 3.91%
1,053,127 $11.1 Million
Q3 2022

Nov 14, 2022

BUY
$13.1 - $20.34 $1.66 Million - $2.58 Million
126,732 Added 14.29%
1,013,455 $18.4 Million
Q2 2022

Aug 12, 2022

BUY
$12.37 - $21.86 $7.57 Million - $13.4 Million
611,696 Added 222.41%
886,723 $12.6 Million
Q1 2022

May 12, 2022

BUY
$15.94 - $23.34 $577,729 - $845,934
36,244 Added 15.18%
275,027 $6.05 Million
Q4 2021

Feb 10, 2022

BUY
$14.76 - $24.89 $3.52 Million - $5.94 Million
238,783 New
238,783 $4.06 Million

Others Institutions Holding AURA

About Aura Biosciences, Inc.


  • Ticker AURA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 29,273,600
  • Market Cap $322M
  • Description
  • Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develop...
More about AURA
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.